We describe a child with dyslexia and difficulty in school who, at the age of 13 years, began to suffer from several head injuries resulting from falls of uncertain cause. Two years later, the patient developed symptoms of a severe mitochondrial disorder (involving bulbar-pyramidal paralysis, ophthalmoplegia, and hyperlactatemia) 
Introduction
Mitochondrial diseases (MID), which develop due to either mitochondrial (mtDNA) or nuclear DNA mu ta tions [13] , are rare. Therefore, the knowledge of these diseases among physicians may be poor, and the diag nosis of these diseases can be delayed. The extremely heterogeneous clinical presentation of mtDNA muta tions may also exacerbate the diagnostic difficulties.
Leigh disease (LS) [7, 11] is a progressive subacute necrotising encephalomyelopathy characterised by focal bilateral lesions in one or more areas of the central nervous system, including the brain stem, thalamus, basal ganglia, cerebellum and spinal cord. These changes may be recognised by magnetic res onance imaging (MRI). In the majority of individuals with LS in Poland, the disease is caused by mutations in nuclear DNA (the SURF1 gene) [6] and is inherited as an autosomal recessive trait. The mitochondrially inherited form (MILS) represents only 1020% of all LS cases [6, 7, 10] .
Although the m.8344A>G mutation in the mtRNA lysine gene (MTTK) is a "common" mtDNA mutation, its prevalence was estimated as relatively low (< 1 : 300 000) [12] . This mutation was originally described in patients with MERRF (myoclonic epilepsy with rag ged red fibres) syndrome [14] , but multiple heteroge neous nonMERRF presentations have been reported [2, 3, 5] . There have also been a number of descrip tions of MILS related to the m.8344A>G mutation [1, 15, 16] .
The aim of this paper is to describe the first Polish patient with lateonset Leigh syndrome caused by an MTTK m.8344A>G mutation. Several factors that may have influenced the natural course of the dis ease, including delayed diagnosis, stress and me di cations used to modify the energetic metabolism of the patient, are discussed.
Material and methods Case report
A 15yearold boy on a respirator, who had been diagnosed with encephalomyelitis, was sent to CMHI for the inclusion in the programme of artificial ven tilation at home.
The boy had developed normally during the neo natal period and infancy. His family history was negative; the parents and two older siblings are all healthy. From early childhood, the patient was under the care of a neurologist, speech therapist and psy chologist due to dyslexia and school difficulties.
Beginning at 13 years of age, the patient suf fered from repeated falls of uncertain cause ("drop attacks"), which were associated with several head injuries. Cardiac involvement was not observed. Val proic acid (VPA) was administered at 14 years due to suspicion of epilepsy, despite the lack of epileptiform discharges on EEG. Approximately five months after VPA administration, limb weakness, double vision, difficulties in swallowing, dyspnoea and stool incon tinence appeared and rapidly developed over several weeks. Respiratory failure occurred and required arti ficial ventilation. Episodes of seizures, impaired con sciousness, and difficulty in controlling blood pres sure were observed at a local paediatric ward. Plasma lactate levels were slightly elevated (24 mg/dl, ref.
< 20 mg/dl). Liver enlargement (6 cm), mild transam inase elevation (< 100 U/l) and hyperammonaemia (300 µg/dl) were found. Initially, neuroinfection was suspected based on the results of borreliosis testing (IgG + antibodies), and relevant therapy was applied. Repeated attempts at extubation failed.
At the age of 15 years, the patient was admitted to the CMHI intensive care ward; his physical devel opment was normal (height 180 cm, weight 63 kg). Due to the initial suspicion of undetermined neu roinfection, the patient was treated with intrave nous immunoglobulins, antibiotics, and steroids. VPA administration was discontinued, and carnitine, vita min B 1 and coenzyme Q were administered. His clin ical condition improved quickly, and after ten days, the boy was weaned from mechanical ventilation and transferred to the neurological ward. Neurologi cal examination revealed the severe bulbopyramidal syndrome. Visual evoked potentials were abnormal.
Laboratory examination did not reveal any signs of infection. The lactate concentration in the plasma (58.3 mg/dl) was high, and that in the cerebrospinal fluid was in the upper range of normal (22.6 mg/dl). The organic acid profile revealed an increased excre tion of lactate and Krebs cycle metabolites as well as the presence of VPA derivatives in the urine.
This time, a mitochondrial disorder was suspect ed, and an open muscle biopsy was performed, con firming mitochondrial pathology. The clinical con dition of the patient showed further gradual improvement (he became able to walk with support), and he was discharged home.
A few months later, the boy was readmitted to CMHI due to further deterioration in speech and movement as well as dyspnoea. Bulbar and pseudobulbar palsy, tetraparesis, generalised hypo tonia, absent deep tendon reflexes, and pathologic reflexes were exacerbated during the implemen tation of an intensive rehabilitation program. The rehabilitation was then stopped, and his neurolog ical status slowly improved. The boy was conscious and well oriented at all times.
After a short period of relative remission at home, rapid neurological progression recurred at the age of 15.5 years. Mechanical ventilation was required for one week. A significant worsening of the patient's condition during infusion of mannitol and glucose was observed. Because these symptoms were noted at least twice, an intravenous glucose tolerance test (IVGTT) was conducted. An abnormal increase in the lactate level (in response to hyperglycaemia) was detected during the test (17 and 36 mg/dl before and 30 min after load, respectively), indicating a dys function at the level of the PDH (pyruvate dehydro genase) complex.
When the diagnosis of the mitochondrial disorder with poor prognosis was established, the patient and his parents chose not to continue insistent the rapy. The boy was discharged home under the home care service of local hospice. There, a ketogenic diet was introduced through the gastrostomy (PEG) tube, and supplementation with coenzyme Q, carnitine and vitamin B 1 (reported to have some beneficial effect in PDH and mitochondrial dysfunction) was contin ued. The neurological status of the patient stabilised for several months. The boy did not require mechan ical ventilation and was able to talk. He experi enced some difficulties in swallowing, and therefore a PEG tube was often used for feeding. He required a wheelchair. The patient gained weight properly and his laboratory tests did not show significant abnor malities. Plasma lactate levels remained normal or at the upper normal limit.
One year later, at the age of 16.5, the boy experi enced a strokelike episode. He died at home at the age of 17 years.
This investigation conformed to the principles outlined in the Declaration of Helsinki, and the study protocol was approved by the Bioethical Commis sion of the Children's Memorial Health Institute.
Brain magnetic resonance imaging and spectroscopy MR brain and spinal cord examinations were ac quired with 1.5 T scanners. The brain protocol in volved the acquisition of T1 and T2weighted imag es, FLAIR sequence, and diffusionweighted images (DWI). Two spinal cord images (T1 and T2weighted) were obtained in two planes each. Contrastenhanced T1weighted images were acquired in all studies.
In vivo multivoxel proton magnetic resonance spectroscopy ( 1 HMRS) was also performed. We used a PRESS 2Dchemical shift imaging (CSI) sequence with the following parameters: TR = 1500; TE = 30 with planar resolution; FOV, 230 mm; matrix size, 16 × 16 cm 2 ; section thickness, 2 cm. Full analyses of the spectra were performed in LC Model software.
Muscle biopsy
A mitochondrial study of the muscle biopsy was performed according to histochemical and spectro photometric methods commonly used in our labo ratory. The assessment included light microscopic examination of frozen sections in the following stains and histochemical reactions: haematoxylin and eosin (HE), modified Gomori trichrome, oil red O, succinate dehydrogenase, NADH dehydrogenase, cytochrome c oxidase (COX), acid phosphatase, myosin ATPase preincubated at pH 4.3, 4.6 and 9.4. The activity of respiratory chain complexes IIV was measured in the muscle homogenate as described [6] .
DNA analysis
Total DNA was extracted from the whole blood of the patient, his two siblings and his mother using a standard phenol/chloroform extraction procedure. The SURF1, MTATP6 and MTTK genes were ampli fied and sequenced in 3130 Genetic Analyzer with BigDye Terminators (Applied Biosystems). Multiplex Ligation Probe Amplification (MLPA) analysis was performed with the SALSA MLPA P125B1 Mitochon dria kit (MRCHolland) according to the manufactu rer's protocol.
Samples preparation for Western blot
Tissue samples kept at -80°C, were defrost, cut into small pieces and resuspended in cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton, 0.1% SDS, 1% sodium deoxycholate) containing inhibitors of proteases (1 mM PMSF and the protein protease inhibitor cocktail). Skeletal muscles were homogeniz ed on ice. Samples were incubated on ice for 20 min and centrifuged at 600 × g for 5 min at 4°C to remove insoluble material. The superna tants were collected and centrifuged at 16 000 × g for 20 min at 4°C. Protein concentration in lysates was determined using Bradford method. Samples for SDSPAGE were denatured in reducing Laemmli loading buffer at 95°C for 5 min.
Western blotting
Tissue lysates (20 mg protein) from muscles (pa tient and healthy control) were separated electropho retically in 8% SDS polyacrylamide gels and trans ferred into PVDF membrane (BioRad). Membranes were blocked and proteins were detected using Mito Profile ® Pyruvate dehydrogenase (PDH) WB Antibody Cocktail (abcam) followed by appropriate secondary APconjugated antibodies (1 : 1000, BioRad).
Results

Electrophysiological findings
The available EEG recordings from the patient demonstrate progressive pathology: periodic epilep tiform discharges (PEDs) at the age of 15 years, tri phasic periodical waves and no spikes after few weeks, and the presence of frontal intermittent rhythmic delta activity (FIRDA) two months later.
Evoked potentials examined at the first rapid deterioration, at the age of 15 years, revealed abnor mal visual evoked potentials. Auditory potentials were not recorded.
Magnetic resonance imaging and spectroscopy
MR examination was performed three times over a year to document the clinical progression of the disease. Reassessment of these MR images show ed that lesions suggesting LS were already present at the first examination, at the age of 14.5 years (not shown). They were milder than those found 6 months later.
The MR examinations at the age of 15 years are shown in the upper portion of Fig. 1 (panels AD) . The cooccurrence of bilateral, symmetrically located lesions in the thalamic region were not mentioned in the first description of the results, although they are clearly visible on diffusionweighted images (Fig. 1B) . Spinal cord imaging performed 10 days later (Fig. 1CD) showed a diffuse abnormal signal in the medulla oblongata, cervical spinal cord and upper portion of the thoracic spinal cord (Th1Th3). Followup brain and spinal canal MR exams tak en at the age of 15.5 years revealed a remarkable progression of both localisations. The bilateral thal amus, putamen, midbrain, pons, medulla oblongata, and entire length of the spinal cord were involved. The lesions were observed predominantly on T2 and diffusionweighted images in the brain (Fig. 1EF ) and on T2weighted images in the spinal cord (Fig.  1GH) .
MR spectroscopy with the voxel localised in the right putamen demonstrated significantly elevated lactate levels and relatively low levels of Cho (Cho/ Cr = 0.26) and NAA (NAA/Cr = 0.94). The levels of Glx (Glx/Cr = 2.7) and mI (mI/Cr = 0.81) were relatively elevated (Fig. 2) .
Histochemical and biochemical findings
Histochemistry of muscle samples revealed few distinct ragged blue fibres (RBF) (Fig. 3 ) accompa nied by a pattern suggestive of mosaic COX defi ciency and mild to moderate lipid accumulation. No classical ragged red fibres (RRF) were observed.
Spectrophotometry of a muscle homogenate show ed an increased citric synthase activity (267.5 nmol/ min/mg protein, ref. < 180 nmol/min/mg protein) and normal activity for respiratory chain complexes IIV (not shown).
Immunoblotting with pyruvate dehydrogenase (PDH) complex antibodies showed a diminished sig nal representing the steady state level of the E1α sub unit in the muscle homogenate (28.7% of the refer ence value), consistent with PDH dysfunction (Fig. 4) .
DNA analysis
A search for the common mutations responsible for LS in the SURF1 and MTATP6 genes was nega tive. MLPA analysis demonstrated a lack of ligation of the m.8344A>Gspecific probe. Further, MTTK gene sequencing confirmed the presence of the m.8344A>G mutation in 96% of his mtDNA. The het eroplasmy levels of this mutation in the patient's sis ter and mother were 80% and 70%, respectively (all family members were asymptomatic).
Discussion
The patient bearing an m.8344G>A mutation (pro band) rapidly developed a full complement of symptoms of the mitochondrial disorder, including muscle weakness, loss of acquired skills, bulbarpyra midal syndrome, ophthalmoplegia, Leigh syndrome, strokelike episodes, elevated lactate concentration, and ragged blue muscle fibres. The first exacerbation (with transient liver enlargement and dysfunction) coincided with VPA administration. The course of the disease had overlapping symptoms of MILS, MERRF and MELAS (mitochondrial encephalopathy, lactic acidosis, strokelike episodes).
Leigh syndrome (LS) is a frequent presentation of the mitochondrial disorder in children, and it oc curs regardless of the molecular aetiology of the mitochondrial pathology. The disease has a peculiar topography and specific pathological morphology [7] . It is not yet understood why LS develops rarely in mitochondrial tRNAmutated patients [16] , more frequently in PDHdeficient patients, and most fre quently in SURF1mutated patients [6] .
According to our hypothesis, episodes of hyper ventilation and hypocapnia increase the risk of LS development [9] . A transient elevation in the intra cellular pH of neurons (respiratory alkalosis) could trigger apoptosis in specially structured regions of the brain affected in LS.
We documented the occurrence of respiratory alkalosis in SURF1-related LS and also described this phenomenon in an LS patient with another MTTK m.8363 mutation [10] . Alkalosis and hypocapnia were not documented in the reported patient, but the occurrence of hyperventilation episodes due to anxiety over his unexpectedly rapid deterioration cannot be excluded.
The proper diagnosis of our patient was delayed by an incorrect recognition of epilepsy and the admin istration of VPA (a known mitochondrial suppres sor), misdiagnosis of infectious encephalomyelitis, and the failure to note the LS in the first brain MRI performed at the local paediatric ward. It should be emphasised that the m.8344A>G mutation could be detected much earlier because the variant is includ ed in DNA screening panel recommended for LS [6] . Early diagnosis could protect the patient from unnec essary procedures and harmful medications. Further, early diagnosis might have prevented (slowed down or even stopped) the rapid progression of LS changes demonstrated in subsequent brain MR examinations.
Interestingly, some features of PDH deficit, in cluding glucose intolerance and low E1alfa subunit expression, which is also known to cause LS [7, 11, 17] , were observed in our patient. Similarly impaired PDH activity was previously described in a patient with an MTTL m.3243A>G mutation [18] . Both of these mtDNA mutations disrupt mitochondrial tRNAs (for lysine and leucine, respectively) and impair mito chondrial protein synthesis [1, 18, 19] . A disruption of the import and/or the misassembly of cytosolic synthesised polypeptides was suggested to explain the PDH defect in the m.3243A>G mutated cells [18] .
The undulating course of the disease, which is a major hallmark of mitochondriopathies, was evi dent in the reported patient. This severely compli cated the evaluation of the therapeutic approaches used. The periods of exacerbation or improvement in our patient were apparently associated with the drugs or medical procedures applied. It is tempting to suggest a causal relationship, e.g. between the administration of VPA [8] (or intensive rehabilita tion) and the clinical deterioration or between the diet manipulation [4, 17] and the remission; however, neither could be conclusively proven in this patient. It should be remembered that random independent fluctuations in the clinical course may imitate a good or bad response to parallel treatments.
Our expanding knowledge of the natural history of m.8344A>Grelated disease reveals a very broad range of symptoms and severity [2, 3, 5 ], regardless of the heteroplasmy level. Multiple environmen tal factors (favourable or damaging) may influence the course of disease in individual patients [4] . This allows speculation that avoiding harmful factors can slow down disease progression, and vice versa. Until the nature of these relationships is finally estab lished, the potential impacts of treatment must be considered in the management of patients with sus pected mitochondrial disease [4] .
In summary: We recommend molecular screen ing for mtDNA (and nDNA) mutations in all patients with symmetric lesions in the subcortical nuclei and other locations characteristic of LS present on brain MR examination. The brain MRI protocol should obligatorily include diffusionweighted (DWI), and T2weighted (T2WI) imaging; LSlike changes should be assessed (or at least consulted on) by a neuroradiologist experi enced in the field.
Valproic acid (VPA) should be avoided as an an ti convulsant drug in patients with a suspected mitochondrial disorder. In cases of severe epilep sy, especially associated with other symptoms of encephalopathy, a mitochondrial pathology of any kind should be carefully considered (i.e. according to Nijmegen criteria) before VPA introduction.
The benefit of a ketogenic diet for mitochon drial tRNAmutated patients cannot be assessed until prospective blinded studies in larger groups of patients are performed. 
